HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PCSA
Processa Pharmaceuticals, Inc.
There isn't enough reported data to score PCSA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PCSA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
PCSA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PCSA PE Valuation
PCSA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PCSA Forward outlook
There aren't enough analyst estimates for PCSA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
PCSA has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus PCSA down 106%.
PCSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$585.00 | -$30.00 |
| Q2 2023 | -$730.00 | -$265.00 |
| Q1 2023 | -$840.00 | -$435.00 |
| Q4 2022 | -$850.00 | -$475.00 |
| Q3 2022 | -$555.00 | +$560.00 |
| Q2 2022 | -$465.00 | +$830.00 |
| Q1 2022 | -$405.00 | +$855.00 |
| Q4 2021 | -$375.00 | +$895.00 |
PCSA is still losing money, but far less than before: $33.50 per share over the past year, against $1,295.00 at its worst in mid-2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PCSA Quarterly Revenue
PCSA's revenue is shrinking: $0 last quarter.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PCSA on cash generation, producing positive trailing cash flow while its opponent burns cash.
PCSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$274.5K |
| Q1 2026 | -$3.6M | -$860.8K |
| Q4 2025 | -$2.9M | -$652.9K |
| Q2 2025 | -$2.3M | +$1.1M |
| Q1 2025 | -$2.7M | -$681K |
| Q4 2024 | -$2.2M | -$123.9K |
| Q2 2024 | -$3.3M | -$1.3M |
| Q1 2024 | -$2M | +$65.2K |
PCSA has burned cash in almost every quarter: −$12M over the past year, against −$11M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PCSA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PCSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +128K shares |
| 1 year | +622% | +2.4M shares |
| 3 years | +8528% | +2.7M shares |
| 5 years | +24836% | +2.7M shares |
PCSA has 3M diluted shares, up 622% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PCSA Net Leverage
PCSA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PCSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.7 | Neutral |
| Stochastic | 45.9 | Neutral |
PCSA's weekly RSI is 42 (neutral) and its Stochastic is 46 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PCSA PE vs Healthcare Sector
PCSA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PCSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.77 | 4% above |
| 20 week MA | $2.04 | 9.8% below |
| 50 week MA | $2.63 | 30% below |
| 100 week MA | $5.96 | 69% below |
| 200 week MA | $80.7 | 98% below |
PCSA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over PCSA on returns for 2026, with the stronger performance.
PCSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6,375.0 | $3,700.0 | -42% |
| 2021 | $3,700.0 | $2,565.0 | -31% |
| 2022 | $2,565.0 | $605.0 | -76% |
| 2023 | $605.0 | $167.3 | -72% |
| 2024 | $167.3 | $22.8 | -86% |
| 2025 | $22.8 | $3.92 | -83% |
| 2026 YTD | $3.92 | $1.84 | -53% |
PCSA has finished every year since 2020 lower, and it's down 53% so far in 2026.